Results 31 to 40 of about 15,406 (277)
Modulation of the GABAergic pathway for the treatment of fragile X syndrome. [PDF]
, 2014 Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation ...
Hagerman, Randi J +2 more
core +1 more source
Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Cochrane Database of Systematic Reviews, 2020 BACKGROUND This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to
Rebecca Bresnahan +4 more
semanticscholar +1 more source
Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats [PDF]
Journal of Clinical and Diagnostic Research, 2013 Background: Vigabatrin is used as the drug of choice in resistant epilepsy and infantile spasms. Ataxia, tremors and abnormal gait have been frequently reported following the use of this drug, indicating an involvement of the cerebellum.
Deepa Singh +2 more
doaj +1 more source
Emerging pharmacotherapy of tinnitus [PDF]
, 2009 Tinnitus, the perception of sound in the absence of an auditory stimulus, is perceived by about 1 in 10 adults, and for at least 1 in 100, tinnitus severely affects their quality of life.
Ana Belén Elgoyhen +43 more
core +1 more source
Perturbação psicótica aguda associada à vigabatrina.
Acta Médica Portuguesa, 2000 Vigabatrin, a drug mainly used in the treatment of therapy-resistant epilepsy, has been associated to a large range of adverse effects, including acute psychotic disorders. The authors report the case of a 44-year-old patient with drug-resistant temporal
M Xavier +3 more
doaj +1 more source
Development of Acute Encephalopathy Due to Vigabatrin Use in a Case of Nonketotic Hyperglycinemia [PDF]
, 2012 A 3-month-old boy with early myoclonic epilepsy owing to nonketotic hyperglycinemia developed acute encephalopathy after - vigabatrin was presented. Due to the use of vigabatrin, the elevated gamma-aminobutyric acid (GABA) concentration in the brain ...
Elif YÜKSEL KARATOPRAK, Sema SALTIK
core +1 more source
Vigabatrin-Induced Peripheral Visual Field Defects in Patients With Refractory Partial Epilepsy [PDF]
, 2010 Purpose: Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction. Previous analyses of results from a prospective, observational study assessing vigabatrin-induced visual field constriction (described below) employed a ...
Bittman, Richard M. +3 more
core +2 more sources
Epilepsia, 1999 Summary:Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter γ‐amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA‐transaminase. This produces an increase in central nervous system (CNS) GABA levels.
openaire +2 more sources
On-Off Intermittency in Time Series of Spontaneous Paroxysmal Activity in Rats with Genetic Absence Epilepsy [PDF]
, 2006 Dynamic behavior of complex neuronal ensembles is a topic comprising a streamline of current researches worldwide. In this article we study the behavior manifested by epileptic brain, in the case of spontaneous non-convulsive paroxysmal activity.
Alexander Hramov +10 more
core +3 more sources
Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors. [PDF]
PLoS ONE, 2012 Vigabatrin (VGB) is a commonly prescribed antiepileptic drug designed to inhibit GABA-transaminase, effectively halting seizures. Unfortunately, VGB treatment is also associated with the highest frequencies of peripheral visual field constriction of any ...
Jin Yang +7 more
doaj +1 more source